Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials [PDF]
Ophthalmology and Therapy, 2023 Introduction This review aims to assess the efficacy, durability and safety of faricimab—a dual vascular endothelial growth factor and angiopoietin 2 inhibitor—in patients with neovascular age-related macular degeneration (nAMD) and diabetic macula ...
Anna Stage Vergmann
exaly +4 more sources
Multidimensional evaluation of the potential impact of faricimab availability on healthcare system accessibility for retinal disease treatment in Poland [PDF]
BMC Health Services ResearchBackground This study aimed to evaluate the impact of introducing faricimab into a publicly funded drug programme for retinal diseases, focusing particularly on reducing treatment frequency and optimising resources.
Michał Seweryn +5 more
doaj +2 more sources
Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
Medicina (Lithuania), 2023 Background and Objectives: Faricimab is the first intravitreal injection of vascular endothelial growth factor-A and angiopoietin-2 bispecific monoclonal antibody.
Yoshiaki Kiuchi
exaly +3 more sources
Cross-Sectional Survey of Real-World Physician Prescribing Practices for Anti-VEGF Agents in the Treatment of Neovascular Age-Related Macular Degeneration and Associated Patient Burden in the United States [PDF]
Clinical OphthalmologyShilpa Gulati,1,2 Emily Coak,3 Daniel Mascia,3 Katherine Li,3 Stella Ko,4 Nicole Gidaya Bonine4 1New England Retina Consultants, Springfield, MA, USA; 2Massachusetts Chan Medical School, University of Massachusetts, Worcester, MA, USA; 3Adelphi Real ...
Gulati S +5 more
doaj +2 more sources
Short term real-world effectiveness of faricimab in neovascular age-related macular degeneration patients in the Republic of Korea [PDF]
Scientific ReportsTo analyze visual and anatomic outcomes of faricimab injection in neovascular age-related macular degeneration (nAMD) in a real-world setting in Korea. We collected data from nAMD patients who received faricimab injection from 2024 to 2025.
Doh Hoon Chung +8 more
doaj +2 more sources
Budget Impact of Faricimab in Neovascular Age-Related Macular Degeneration in the Netherlands: A Systematic Review and Meta-Analysis of Injection Count [PDF]
Ophthalmology and TherapyIntroduction Frequent anti-vascular endothelial growth factor (anti-VEGF) injections for the treatment of neovascular age-related macular degeneration (nAMD) burden patients and healthcare systems.
Mohamed El Alili +5 more
doaj +2 more sources
Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China [PDF]
Journal of Comparative Effectiveness ResearchAim: Diabetic macular edema (DME) is one of the leading causes of vision impairment in diabetic patients. The aim of this study was to evaluate the cost-effectiveness of faricimab (Vabysmo R ), the first bispecific antibody targeting VEGF-A and ANG-2,
Fenghao Shi +6 more
doaj +2 more sources
Switching to faricimab from aflibercept during maintenance treatment period for age-related macular degeneration [PDF]
Scientific ReportsTo compare the short-term treatment outcomes of aflibercept and faricimab for neovascular age-related macular degeneration (nAMD) during the maintenance treatment period, we included 82 eyes of 74 patients who switched from aflibercept to faricimab ...
Misa Masaoka, Kenji Yamashiro
doaj +2 more sources
LifeFaricimab is a newly approved bispecific antibody for neovascular age-related macular degeneration (nAMD). Our study aims to evaluate clinical outcomes of faricimab switching in patients with treatment-refractory nAMD; determine parameters that predict ...
Matthew Azzopardi
exaly +3 more sources
Quantitative analysis of vitreous changes in intraocular inflammation following faricimab treatment in a real world setting [PDF]
International Journal of Retina and VitreousBackground To analyze the incidence, and clinical characteristics of intraocular inflammation (IOI) associated with faricimab in a tertiary center in Austria.
Clemens Thürridl +6 more
doaj +2 more sources